Evidence map›Paper›PMID 37377842›Full record

ArticleJournal of hepatocellular carcinoma2023

Comparison of Ablation Volume Between Emprint

Toru Ishikawa, Iori Hasegawa, Hiroshi Hirosawa, Tsubasa Honmou, Nobuyuki Sakai, Takanori Igarashi, Shun Yamazaki, Takamasa Kobayashi, Toshifumi Sato, Akito Iwanaga and 3 more

Abstract read
In one paragraph

Article in Journal of hepatocellular carcinoma, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Toru IshikawaDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.ORCID 0000-0002-5470-9694
Iori HasegawaDepartment of Clinical Engineering, Saiseikai Niigata Hospital, Niigata, Japan.
Hiroshi HirosawaDepartment of Clinical Engineering, Saiseikai Niigata Hospital, Niigata, Japan.
Tsubasa HonmouDepartment of Clinical Engineering, Saiseikai Niigata Hospital, Niigata, Japan.
Nobuyuki SakaiDepartment of Clinical Engineering, Saiseikai Niigata Hospital, Niigata, Japan.
Takanori IgarashiDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Shun YamazakiDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Takamasa KobayashiDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Toshifumi SatoDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Akito IwanagaDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Tomoe SanoDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Junji YokoyamaDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Terasu HonmaDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.ORCID 0000-0002-4959-7958

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Microwave ablation (MWA) is a standard percutaneous local therapy for hepatocellular carcinoma (HCC). Next-generation MWA is reported to create a more spherical ablation zone than radiofrequency ablation (RFA). We compared the ablation zone and aspect ratio of two 2.45 GHz MWA ablation probes; Emprint Materials and Methods: We included 20 patients with HCC, with an average tumour diameter of 33.2 ± 12.2 mm, who underwent MWA using Emprint Results: The aspect ratios in the Emprint Conclusion: There was no significant difference in the aspect ratios of the ablation diameter, and the ablation zone was almost spherical in both cases. Mimapro

Indexed as

ablation zonehepatocellular carcinomamicrowave ablation

Identifiers

PMID37377842
PMCPMC10292608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.